View in EDS HTML Full Text PDF Full Text

Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.

Saved in:
Bibliographic Details
Title: Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.
Authors: Mitchell J; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. jonathan.mitchell@astrazeneca.com., Camacho N; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Shea P; Institute for Genomic Medicine, Columbia University, New York, NY, USA., Stopsack KH; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA., Joseph V; Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Burren OS; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Dhindsa RS; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA., Nag A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Berchuck JE; Dana-Farber Cancer Institute, Boston, MA, USA., O'Neill A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Abbasi A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Zoghbi AW; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA., Alegre-Díaz J; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico., Kuri-Morales P; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico.; Instituto Tecnológico y de Estudios Superiores de Monterrey, Tecnológico, Monterrey, Nuevo León, Mexico., Berumen J; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico., Tapia-Conyer R; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico., Emberson J; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Torres JM; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Collins R; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Wang Q; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA., Goldstein D; Institute for Genomic Medicine, Columbia University, New York, NY, USA., Matakidou A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Haefliger C; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Anderson-Dring L; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., March R; Precision Medicine and Biosamples, R&D Oncology, AstraZeneca, Dublin, Ireland., Jobanputra V; Institute for Genomic Medicine, Columbia University, New York, NY, USA.; Department of Pathology and Cell Biology, Columbia University, New York, NY, USA., Dougherty B; Oncology R&D, AstraZeneca, Waltham, MA, USA., Carss K; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Petrovski S; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Kantoff PW; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Convergent Therapeutics, Cambridge, MA, USA., Offit K; Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Mucci LA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; American Cancer Society, Atlanta, GA, USA., Pomerantz M; Dana-Farber Cancer Institute, Boston, MA, USA., Fabre MA; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. margarete.fabre@astrazeneca.com.; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. margarete.fabre@astrazeneca.com.; Department of Haematology, University of Cambridge, Cambridge, UK. margarete.fabre@astrazeneca.com.
Source: Nature communications [Nat Commun] 2025 Feb 19; Vol. 16 (1), pp. 1779. Date of Electronic Publication: 2025 Feb 19.
Publication Type: Journal Article; Meta-Analysis
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-025-56944-1